SS-31 Dosage: Research Doses, Protocols, and Safety

There is no single standard SS-31 dosage for humans. In published clinical research, elamipretide — the scientific name for SS-31 — has most often been given as 40 mg once daily by subcutaneous injection, while older infusion studies used weight-based rates such as 0.05 mg/kg per hour. Outside of one narrow FDA-approved indication, SS-31 is sold strictly as a research chemical, and no verified self-administered human dose exists.

What SS-31 (Elamipretide) Actually Is

SS-31 is a short synthetic tetrapeptide designed to concentrate inside mitochondria, the structures that produce most of a cell's energy. It is also known as elamipretide, MTP-131, and Bendavia, depending on which study or vendor label you are reading.

The ss 31 peptide works by binding to cardiolipin, a lipid on the inner mitochondrial membrane. Researchers believe that interaction helps stabilize the membrane and reduce oxidative stress, which is why SS-31 shows up in studies of heart failure, mitochondrial myopathy, kidney injury, and dry age-related macular degeneration.

SS-31 is not a stimulant, a hormone, or a fat-loss compound. Its proposed mechanism is structural and antioxidant-related, and much of the human evidence remains early or mixed.

SS-31 Doses Used in Published Clinical Research

The table below summarizes doses that appear in peer-reviewed human and animal work. These are study doses, not recommendations for personal use.

Research context	Dose studied	Route	Notes
Barth syndrome (TAZPOWER)	40 mg once daily	Subcutaneous	Basis for the 2025 FDA approval of Forzinity in patients weighing at least 30 kg
Primary mitochondrial myopathy (MMPOWER)	40 mg once daily	Subcutaneous	Six-minute walk and fatigue endpoints; results were mixed
Heart failure (EMBRACE-HF)	0.05 mg/kg per hour	IV infusion	Short infusions targeting cardiac pressure endpoints
Dry AMD (ReCLAIM)	40 mg once daily	Subcutaneous	Retinal structure and visual function measures
Early infusion studies	0.05–0.25 mg/kg per hour	IV infusion	Higher rates were tied to more infusion-site reactions
Preclinical animal models	1–5 mg/kg per day	Injection or infusion	Laboratory models only; not transferable to humans

The pattern across trials is a steady move toward a flat 40 mg subcutaneous dose rather than weight-based infusion rates. Even so, dose selection in research depends on the condition, the endpoint, and the trial phase.

Planning an SS-31 Dosing Protocol in the Lab

A laboratory ss-31 dosing protocol usually begins with concentration math, not a target dose. Researchers dissolve lyophilized powder in bacteriostatic water or another suitable solvent, then calculate how much volume delivers the amount required for a given assay or animal model.

Vial size and the volume of solvent determine the final concentration, which is why two labs using the same vial can end up with very different numbers.

Vial size	Solvent added	Final concentration	Volume containing 1 mg
10 mg	1 mL	10 mg/mL	0.1 mL
10 mg	2 mL	5 mg/mL	0.2 mL
10 mg	5 mL	2 mg/mL	0.5 mL
50 mg	5 mL	10 mg/mL	0.1 mL

Anyone comparing ss-31 reconstitution and dosage figures should confirm whether the number refers to the powder weight, the reconstituted concentration, or the injected volume. Mixing those three up is the most common source of confusion.

What People Report in Online Communities

Self-reported numbers online span a much wider range than clinical trials do. In ss-31 dosage reddit discussions and similar forums, users describe anything from 1 mg to 10 mg per day, often injected subcutaneously, and frequently alongside other peptides.

Those reports carry real limitations:

• No verification that the vial contains elamipretide at the labeled strength
• No purity testing, sterility testing, or dosing oversight
• No follow-up labs, so side effects are rarely documented
• Strong placebo effects in energy and fatigue self-ratings

Community anecdotes are not evidence of safety or effectiveness, and they should never be treated as a substitute for a clinician's guidance.

Combining SS-31 With MOTS-c

MOTS-c is a mitochondrial-derived peptide studied for its role in metabolic regulation and AMPK signaling. Because both compounds act on mitochondrial biology, people often ask about ss-31 and mots-c together.

The two are not interchangeable. SS-31 targets membrane lipids, while MOTS-c influences gene expression and fuel metabolism. No published human trial has tested the combination, so any interaction, additive effect, or overlapping toxicity is unknown.

Stacking also complicates attribution. If a side effect appears, there is no clean way to tell which compound caused it.

Safety, Sourcing, and Legal Status

SS-31 has one narrow FDA-approved use and no approved general use. In the United States, the only legal human indication is the branded product Forzinity, prescribed for Barth syndrome in patients weighing at least 30 kg.

Vials sold online as "SS-31 peptide" are marketed for laboratory research only. They are typically not produced under pharmaceutical manufacturing standards, which means identity, purity, and sterility can vary from batch to batch.

In clinical trials, the most commonly reported side effects were injection-site reactions, headache, nausea, and fatigue. Long-term safety data in healthy adults do not exist, and the compound has not been evaluated in pregnancy, breastfeeding, or children outside specific trial settings.

Anyone considering SS-31 for a health condition should talk with a healthcare professional rather than rely on forum dosing or vendor marketing.

Key Takeaways on SS-31 Dosage

• No universal human SS-31 dosage has been established outside of the approved Barth syndrome indication.
• The most common dose in modern clinical trials is 40 mg subcutaneously once daily.
• Earlier heart failure trials used weight-based IV infusions of 0.05 mg/kg per hour.
• SS-31 is not FDA-approved for general human use in the United States.
• Research-grade SS-31 is not manufactured to pharmaceutical standards, so purity and sterility are not guaranteed.
• Community-reported doses vary widely and are not supported by controlled evidence.
• Combining SS-31 with MOTS-c has not been studied in humans.

Dose, route, and duration all change what a study measures, which is why a single "SS-31 dosage" number cannot describe the whole field.

COMMON QUESTIONS

Frequently Asked Questions

What is the typical SS-31 dosage?

The most common dose in recent clinical trials is 40 mg once daily by subcutaneous injection. Earlier heart failure studies used intravenous infusions of about 0.05 mg/kg per hour. There is no single standard dose, and self-administered doses reported online are not supported by controlled research.

Is SS-31 FDA approved for human use?

SS-31 is FDA-approved only as Forzinity (elamipretide) for Barth syndrome in patients weighing at least 30 kg. It is not approved for general use, anti-aging, athletic performance, or metabolic conditions. Vials sold online are labeled for laboratory research only and are not intended for human use.

Can SS-31 be stacked with MOTS-c?

No published human trial has tested SS-31 and MOTS-c together, so any interaction or additive risk is unknown. The two peptides work through different mitochondrial mechanisms. Stacking also makes it impossible to tell which compound is responsible for a side effect, so medical supervision is essential.